Daratumumab represents an important addition to the armamentarium of care for improving patient outcomes, said Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Daratumumab, alone and in combination with a proteasome inhibitor and immunomodulation, represents an important addition to the armamentarium of care for improving patient outcomes, especially response rate and progression-free survival, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Transcript
Why have immunomodulatory drugs been so successful in relapsed/refractory multiple myeloma?
I think we've learned that immunomodulatory agents like lenalidomide [Revlimid] and pomalidomide have been quite effective. I think if you go back a couple of steps in terms of how we've got to where we are today, we saw thalidomide become a really important component of care. We're kind of moving then from that older chemotherapy-based regimen approach. You saw agents like thalidomide coming forward—brand new mechanism of action, modulating the microenvironment and seeing improvements. We then saw proteasome inhibitors [PIs] come forward, like Velcade. And then we saw them being used by themselves, then we saw them being used with IMiDs [immunomodulatory drugs].
And I think today what we see is that IMiDs are an important component of care. But going back to daratumumab for a second, I think that if you look at the magnitude of benefit that we're adding when we're adding daratumumab to these regimens, it's really clear today that daratumumab is in itself a critical, essential agent in terms of improving outcomes for patients.
And so I think we're at a point now where we can build regimens, like daratumumab plus a PI plus an IMiD, and we can get these very, very high response rates, depth of response, and improvement in PFS [progression-free survival]. And I think building those regimens today is really important. But I think daratumumab is a key part of that, and an IMiD is a piece of that, whether it be thalidomide, Revlimid, or pomalidomide.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More